Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Sanofi is the lead sponsor of 133 current clinical trials in our USA, China, UK, India, Ireland and EU (CTIS) registers. 59 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Dupilumab, Frexalimab and Rilzabrutinib. The most-studied condition is Healthy Volunteers.

Company profiles on this site (news, sites, medicines, approvals): Sanofi Ireland (IE) →Sanofi SA (FR) →

ClinicalTrials.gov trials by status

Recruiting5950%
Active, closed5446%
By invitation54%

Trials by phase

Phase 34437%
Phase 23530%
Observational1513%
Phase 4108%
Phase 1/2108%
Phase 2/322%
Phase 122%

Clinical trials sponsored by Sanofi

118 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease NCT07190196 · Immunoglobulin G4 Related Disease Drug: Rilzabrutinib	Phase 3	Recruiting	2025-09	UK, USA, China
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation NCT07412470 · Kidney Transplant Rejection Drugs: Frexalimab, Methylprednisolone, Mycophenolate Mofetil	Phase 2/3	Recruiting	2026-03	UK, USA, China
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS) NCT02991469 · Juvenile Idiopathic Arthritis Drug: Sarilumab	Phase 2	Recruiting	2018-08	Ireland, UK
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype NCT07190222 · Chronic Obstructive Pulmonary Disease Drug: Lunsekimig	Phase 3	Recruiting	2025-09	UK, USA, China
Phase 1b/2 Study of IV Sarilumab in Adult With RA NCT07704580 · Rheumatoid Arthritis Drug: Sarilumab	Phase 1/2	Recruiting	2026-07	USA
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease NCT06975865 · Sickle Cell Disease Drug: Rilzabrutinib	Phase 3	Recruiting	2025-08	UK, USA
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis NCT06975722 · Ulcerative Colitis Drug: SAR442970	Phase 2	Recruiting	2025-07	UK, USA, China
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment NCT07290803 · Atopic Dermatitis	Observational	Recruiting	2025-11	USA, China
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction NCT06082037 · Lung Transplant Rejection Drugs: Azithromycin, Belumosudil	Phase 3	Recruiting	2023-10	USA, China
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis NCT07185009 · Ulcerative Colitis Drug: Duvakitug	Phase 3	Recruiting	2026-01	USA
A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease NCT06984627 · Graves' Disease	Phase 2	Recruiting	2025-09	UK
A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD) NCT07793409 · ClinicalTrials.gov ↗ · Chronic Obstructive Pulmonary Disease Drug: Lunsekimig	Phase 3	Recruiting	2026-09	UK, USA
A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission NCT07156175 · ClinicalTrials.gov ↗ · Microscopic Colitis	Phase 2	Recruiting	2025-10	UK
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B NCT07285460 · ClinicalTrials.gov ↗ · Hemophilia Drugs: Antithrombin, Clotting factor concentrates, Fitusiran	Phase 3	Recruiting	2025-12	USA, India, China
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) NCT06290141 · ClinicalTrials.gov ↗ · Chronic Inflammatory Demyelinating Polyneuropathy Drugs: IVIG, Riliprubart	Phase 3	Recruiting	2024-08	UK, USA, China
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype NCT07190209 · ClinicalTrials.gov ↗ · Chronic Obstructive Pulmonary Disease Drug: Lunsekimig	Phase 3	Recruiting	2025-09	UK, USA, China
Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) NCT07457580 · ClinicalTrials.gov ↗ · Type 1 Diabetes Drug: Teplizumab	Observational	Recruiting	2026-03	UK
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) NCT05263206 · ClinicalTrials.gov ↗ · Pruritus Drugs: Dupilumab, Fexofenadine	Phase 3	Recruiting	2022-02	USA, China
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease NCT07688213 · Dementia, Alzheimer's Type, Alzheimer's Disease	Phase 2	Recruiting	2026-07	USA
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa NCT07170917 · ClinicalTrials.gov ↗ · Hidradenitis Suppurativa Drug: Brivekimig	Phase 2	Recruiting	2025-11	UK, USA, China
Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and Older NCT07810010 · ClinicalTrials.gov ↗ · Respiratory Syncytial Virus, Human Metapneumovirus, Healthy Volunteers	Phase 2	Recruiting	2026-09	UK
iGlarLixi CGM Study in Chinese T2D Individuals After OADs NCT06671587 · ClinicalTrials.gov ↗ · Type 2 Diabetes (T2D) Drug: IGlarLixi	Phase 4	Recruiting	2024-12	China
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. NCT07053423 · ClinicalTrials.gov ↗ · Chronic Obstructive Pulmonary Disease Drug: Dupilumab	Phase 4	Recruiting	2025-09	UK, USA, China
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease NCT06500702 · ClinicalTrials.gov ↗ · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion Drugs: Brivekimig, Frexalimab, Rilzabrutinib	Phase 2	Recruiting	2024-12	UK, USA, China
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease NCT07184931 · ClinicalTrials.gov ↗ · Crohn's Disease Drug: Duvakitug	Phase 3	Recruiting	2025-10	UK, USA, China
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease NCT06958536 · ClinicalTrials.gov ↗ · Crohn's Disease Drug: SAR442970	Phase 2	Recruiting	2025-06	UK, USA, China
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma NCT06356571 · ClinicalTrials.gov ↗ · Plasma Cell Myeloma Refractory Drugs: Acetaminophen, Carfilzomib, Dexamethasone	Phase 2	Recruiting	2025-03	USA
A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1 NCT06844214 · ClinicalTrials.gov ↗ · Myotonic Dystrophy	Phase 1/2	Recruiting	2025-07	UK, USA
A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice NCT07556159 · ClinicalTrials.gov ↗ · Asthma	Observational	Recruiting	2026-04	USA
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration NCT07215234 · ClinicalTrials.gov ↗ · Geographic Atrophy	Phase 1/2	Recruiting	2025-10	UK, USA
Avalglucosidase Alfa Pregnancy Study NCT05734521 · ClinicalTrials.gov ↗ · Pompe Disease, Pregnancy Drug: Avalglucosidase alfa	Observational	Recruiting	2022-10	USA
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes NCT07088068 · ClinicalTrials.gov ↗ · Type 1 Diabetes Mellitus Drug: Teplizumab	Phase 3	Recruiting	2025-08	UK, USA, China
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis NCT07184996 · ClinicalTrials.gov ↗ · Ulcerative Colitis Drug: Duvakitug	Phase 3	Recruiting	2025-10	USA, China
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK) NCT07116031 · ClinicalTrials.gov ↗ · Chronic Graft Versus Host Disease Drug: Belumosudil	Phase 2	Recruiting	2025-12	UK, USA, China
A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD) NCT06192576 · ClinicalTrials.gov ↗ · Niemann-Pick Diseases, Acid Sphingomyelinase Deficiency	Observational	Recruiting	2024-04	USA
Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above. NCT07779408 · ClinicalTrials.gov ↗ · Healthy Volunteers, Influenza	Phase 1/2	Recruiting	2026-08	USA
A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab NCT06145373 · ClinicalTrials.gov ↗ · Hemophilia A Drugs: Antithrombin, Clotting factor concentrates, Emicizumab	Phase 4	Recruiting	2024-03	USA
The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry NCT07612878 · ClinicalTrials.gov ↗ · COPD (Chronic Obstructive Pulmonary Disease) Drug: Dupilumab	Observational	Recruiting	2026-08	USA
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease NCT07247188 · ClinicalTrials.gov ↗ · Sickle Cell Disease Drugs: 20vPCV, Capvaxive	Phase 3	Recruiting	2026-01	USA
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors NCT05584670 · ClinicalTrials.gov ↗ · Solid Tumor Drugs: ADG126, Bevacizumab, Cetuximab	Phase 1/2	Recruiting	2022-11	USA
A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer NCT07692204 · ClinicalTrials.gov ↗ · Gastric Cancer, Oesophageal Carcinoma Drug: SAR445877	Phase 2	Recruiting	2026-07	China
A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States NCT07260110 · ClinicalTrials.gov ↗ · Type 1 Diabetes Drug: Teplizumab	Observational	Recruiting	2025-10	USA
Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP) NCT06968975 · ClinicalTrials.gov ↗ · Polyneuropathy, Inflammatory Demyelinating, Chronic	Observational	Recruiting	2025-04	USA
Validation of Chlamydia Diagnostic Codes in TriNetX US EHR Data NCT07094373 · ClinicalTrials.gov ↗ · Chlamydial Infections	Observational	Recruiting	2025-01	USA
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease NCT07184944 · ClinicalTrials.gov ↗ · Crohn's Disease Drug: Duvakitug	Phase 3	Recruiting	2026-01	USA
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa NCT07225569 · ClinicalTrials.gov ↗ · Hidradenitis Suppurativa	Phase 2	Recruiting	2025-12	USA, China
A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma NCT06630806 · ClinicalTrials.gov ↗ · Plasma Cell Myeloma Refractory	Phase 1	Recruiting	2024-10	USA
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis NCT07325292 · ClinicalTrials.gov ↗ · Multiple Sclerosis Drugs: Frexalimab, MRI contrast-enhancing preparations	Phase 3	Recruiting	2026-01	USA, China
Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica NCT07286214 · ClinicalTrials.gov ↗ · Polymyalgia Rheumatica Drug: Sarilumab	Phase 4	Recruiting	2026-05	USA
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy NCT06941870 · ClinicalTrials.gov ↗ · Factor VIII Deficiency Drug: Efanesoctocog alfa	Phase 4	Recruiting	2025-09	USA
Long-Term Outcomes of Teplizumab in Routine Clinical Care NCT07360080 · ClinicalTrials.gov ↗ · Type 1 Diabetes Drug: Teplizumab	Observational	Recruiting	2026-03	USA
Registry for Stage 2 Type 1 Diabetes NCT06481904 · ClinicalTrials.gov ↗ · Type 1 Diabetes	Observational	Recruiting	2024-09	USA
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China NCT07710872 · ClinicalTrials.gov ↗ · Meningococcal Infection, Healthy Volunteers	Phase 3	Recruiting	2026-08	China
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis NCT06293053 · ClinicalTrials.gov ↗ · Prurigo Nodularis Drug: Dupilumab	Phase 3	Recruiting	2024-05	USA
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment NCT07007962 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia Drug: Rilzabrutinib	Phase 3	Recruiting	2025-10	USA
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia NCT07086976 · ClinicalTrials.gov ↗ · Autoimmune Haemolytic Anaemia Drug: Rilzabrutinib	Phase 3	Recruiting	2025-08	USA, China
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older NCT07734649 · ClinicalTrials.gov ↗ · Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers Drug: HMPV vaccine	Phase 1/2	Recruiting	2026-07	USA
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol NCT04643002 · ClinicalTrials.gov ↗ · Plasma Cell Myeloma Refractory Drugs: Belantamab mafodotin, Belumosudil, Dexamethasone	Phase 1/2	Recruiting	2021-01	USA
Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age NCT07348692 · ClinicalTrials.gov ↗ · Pneumococcal Immunization, Healthy Volunteers Drug: PCV21 vaccine	Phase 3	Recruiting	2026-01	USA
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma NCT06609239 · ClinicalTrials.gov ↗ · Asthma Drug: Lunsekimig	Phase 2	By invitation	2024-09	UK, USA, India, China
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study NCT06914908 · ClinicalTrials.gov ↗ · Chronic Rhinosinusitis With Nasal Polyps Drugs: Lunsekimig, Mometasone furoate	Phase 2	By invitation	2025-05	UK, USA
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab NCT05669989 · Plasma Cell Myeloma Drugs: Carfilzomib, Cemiplimab, Dexamethasone	Phase 2	By invitation	2023-04	USA, China
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP NCT06859099 · ClinicalTrials.gov ↗ · Polyneuropathy, Inflammatory Demyelinating, Chronic Drug: Riliprubart	Phase 3	By invitation	2025-04	UK, USA, China
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS) NCT06191315 · ClinicalTrials.gov ↗ · Wheezing, Asthma Drug: Dupilumab	Phase 3	By invitation	2024-01	UK, USA
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis NCT05983068 · Dermatitis Atopic Drug: Dupilumab	Phase 4	Active, closed	2024-02	UK, USA
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. NCT06143891 · Chronic Graft Versus Host Disease Drugs: Belumosudil, Prednisolone, Prednisone	Phase 3	Active, closed	2024-01	UK, USA, China
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma NCT05097287 · Asthma Drug: Dupilumab	Phase 4	Active, closed	2021-12	Ireland, UK, USA, India, China
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. NCT06637631 · Crohn's Disease Drug: SAR441566	Phase 2	Active, closed	2024-12	USA, India, China
Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration NCT01736592 · Stargardt's Disease	Phase 2	Active, closed	2012-12	USA
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis NCT06407934 · Dermatitis Atopic Drug: Amlitelimab	Phase 3	Active, closed	2024-05	UK, USA, India, China
Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 NCT05222906 · Gaucher's Disease Type III Drugs: Imiglucerase, Venglustat	Phase 3	Active, closed	2022-04	UK, USA, China
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration NCT06660667 · Neovascular Age-related Macular Degeneration	Phase 1/2	Active, closed	2024-11	UK, USA
Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India NCT07109297 · ClinicalTrials.gov ↗ · RSV Immunization Drug: Nirsevimab	Phase 4	Active, closed	2025-07	India
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps NCT06834360 · Chronic Rhinosinusitis With Nasal Polyps Drugs: Itepekimab, Mometasone furoate	Phase 3	Active, closed	2025-02	UK, USA, China
Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule NCT06812988 · Type 1 Diabetes Mellitus Drug: Brivekimig	Phase 2	Active, closed	2025-02	USA
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma NCT04270409 · ClinicalTrials.gov ↗ · Plasma Cell Myeloma Drugs: Acetaminophen, Dexamethasone, Diphenhydramine	Phase 3	Active, closed	2020-06	Ireland, UK, USA, China
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema NCT05897424 · ClinicalTrials.gov ↗ · Alpha 1-Antitrypsin Deficiency, Emphysema	Phase 2	Active, closed	2024-06	Ireland, UK, USA
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials NCT05492578 · ClinicalTrials.gov ↗ · Dermatitis Atopic Drug: Amlitelimab	Phase 2/3	Active, closed	2022-08	UK, USA, India, China
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis NCT06141486 · ClinicalTrials.gov ↗ · Multiple Sclerosis Drug: Frexalimab	Phase 3	Active, closed	2023-12	UK, USA, India, China
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. NCT06372145 · ClinicalTrials.gov ↗ · Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis Drug: Teriflunomide	Phase 3	Active, closed	2024-04	UK, USA, India, China
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis NCT05769777 · ClinicalTrials.gov ↗ · Dermatitis Atopic Drug: Amlitelimab	Phase 2	Active, closed	2023-04	UK, USA, India, China
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis NCT05588843 · ClinicalTrials.gov ↗ · Colitis Ulcerative	Phase 2	Active, closed	2022-11	UK, USA, India, China
A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia NCT05662319 · ClinicalTrials.gov ↗ · Hemophilia Drugs: Antithrombin, Clotting factor concentrates, Fitusiran	Phase 3	Active, closed	2023-02	USA, India, China
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis NCT06867094 · ClinicalTrials.gov ↗ · Colitis Ulcerative Drug: SAR441566	Phase 2	Active, closed	2025-03	USA, India, China
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant NCT03319667 · Plasma Cell Myeloma Drugs: Bortezomib, Dexamethasone, Isatuximab SAR650984	Phase 3	Active, closed	2017-12	USA, China
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease NCT06557772 · ClinicalTrials.gov ↗ · Coeliac Disease, Celiac Disease Drug: Amlitelimab	Phase 2	Active, closed	2024-08	UK, USA
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis NCT06141473 · ClinicalTrials.gov ↗ · Multiple Sclerosis Drugs: Frexalimab, Teriflunomide	Phase 3	Active, closed	2023-12	UK, USA, India, China
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM NCT05405166 · ClinicalTrials.gov ↗ · Plasma Cell Myeloma Recurrent Drugs: Dexamethasone, Diphenhydramine, Isatuximab	Phase 3	Active, closed	2022-06	UK, USA, China
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma NCT06676319 · ClinicalTrials.gov ↗ · Asthma Drugs: Budesonide/Formoterol, Lunsekimig	Phase 2	Active, closed	2024-11	UK, USA, China
An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps NCT07424144 · ClinicalTrials.gov ↗ · Chronic Rhinosinusitis With Nasal Polyps Drug: Itepekimab	Phase 3	Active, closed	2026-03	UK, USA, China
Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa NCT04910776 · ClinicalTrials.gov ↗ · Glycogen Storage Disease Type II Drug: Avalglucosidase alfa	Phase 3	Active, closed	2021-09	UK, USA, China
Observational Evaluation of Atopic Dermatitis in Pediatric Patients NCT03687359 · Dermatitis Atopic	Observational	Active, closed	2019-08	USA, China
A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease NCT05206773 · ClinicalTrials.gov ↗ · Fabry Disease Drug: Venglustat	Phase 3	Active, closed	2022-03	UK, USA, China
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study NCT05991323 · Prurigo Nodularis Drug: Dupilumab	Observational	Active, closed	2023-12	USA, China
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps NCT06834347 · ClinicalTrials.gov ↗ · Chronic Rhinosinusitis With Nasal Polyps Drugs: Itepekimab, Mometasone furoate	Phase 3	Active, closed	2025-02	UK, USA
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease NCT05280548 · ClinicalTrials.gov ↗ · Fabry Disease Drugs: Migalastat, Venglustat	Phase 3	Active, closed	2022-05	UK, USA, China
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy Participants NCT07646548 · Healthy Volunteers Drug: Dupilumab	Phase 1	Active, closed	2026-06	USA
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor NCT06241118 · ClinicalTrials.gov ↗ · Dermatitis Atopic Drugs: Amlitelimab, Pimecrolimus, Tacrolimus	Phase 3	Active, closed	2024-02	UK, USA, China
A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD) NCT04848779 · ClinicalTrials.gov ↗ · Glycogen Storage Disease Type II	Observational	Active, closed	2021-06	UK, USA
Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis NCT04879628 · ClinicalTrials.gov ↗ · Multiple Sclerosis Drugs: Frexalimab, MRI contrast-enhancing preparations	Phase 2	Active, closed	2021-06	USA

Showing the 100 most recently updated of 118 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Sanofi in the EU trials register (CTIS)

15 trials

Authorised or ongoing trials in the EU Clinical Trials Information System with Sanofi as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
AIRITY: A hybrid cross-sectional and prospective study to assess patient characteristics, disease burden, disease control, phenotypes, endotypes, and outcomes in a real-world setting in patients with asthma 2025-524916-13-00 · Respiratory Tract Diseases	Phase 4	Authorised	France, Spain, Germany + 1 more
EFC18362 - A Phase 3, multicenter, multinational, randomized, open-label, active-comparator study to evaluate the efficacy and safety of venglustat compared with Cerezyme in pediatric participants 2 to 11 years of age with Gaucher disease type 3 who have reached therapeutic goals with enzyme replacement therapy 2026-525374-19-00 · Immune System Diseases Drug: Imiglucerase	Phase 3	Authorised	Hungary, Italy, France + 3 more
A parallel group, Phase 3, randomized, open-label, 2-arm study to demonstrate the superiority of belumosudil versus best available therapy (BAT) in participants at least 12 years of age with chronic graft versus host disease (cGVHD) refractory to or recurrent after 2 to 5 prior lines of systemic therapy 2026-525913-30-00 · Immune System Diseases Drugs: Belumosudil, Bortezomib, Carfilzomib	Phase 3	Authorised	Belgium, Czechia, Hungary + 19 more
A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 48-week SAR448851 treatment followed by open-label extension in participants with early Alzheimer’s disease. 2025-524581-14-00 · Nervous System Diseases	Phase 2	Authorised	Spain, Germany
Study to assess the plasma concentration of rilzabrutinib given as a tablet to adult participants with severe renal impairment compared to matched participants with normal renal function 2026-525707-27-00 · Immune System Diseases	Phase 1	Authorised	Germany
A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants with Non-Cystic Fibrosis Bronchiectasis (NCFB). 2025-523403-29-00 · CTIS ↗ · Respiratory Tract Diseases	Phase 2	Authorised	Poland, Spain, France + 2 more
A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) who participated in either EFC18418 or EFC18419 clinical studies 2025-522983-33-00 · CTIS ↗ · Respiratory Tract Diseases Drug: Itepekimab	Phase 3	Ongoing	Germany, Netherlands, Portugal + 12 more
A multinational, multicenter extension study to investigate the long-term safety, tolerability and efficacy of balinatunfib in adults with Crohn’s disease or ulcerative colitis 2025-522511-42-00 · CTIS ↗ · Digestive System Diseases	Phase 2	Ongoing	Belgium, Germany, Czechia + 11 more
An open label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301 2025-522896-27-00 · CTIS ↗ · Respiratory Tract Diseases	Phase 2	Ongoing	Poland, Italy, Belgium + 6 more
A seamless Phase 2/3 randomized, open-label study to investigate efficacy and safety of frexalimab versus tacrolimus in adult kidney transplant recipients 2025-521521-33-00 · CTIS ↗ · Immune System Diseases Drugs: Frexalimab, Tacrolimus	Phase 3	Ongoing	Germany, Hungary, Italy + 9 more
A Phase 1 first-in-human study to evaluate SAR447754 in healthy adult participants and in adult participants with moderate-to-severe atopic dermatitis. 2025-523826-41-00 · CTIS ↗ · Immune System Diseases	Phase 1	Ongoing	Belgium, Czechia, France + 4 more
An open-label, parallel, Phase 3, two-arm study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to less than 12 years with hemophilia A or B with or without inhibitory antibodies to Factors VIII or IX 2025-521858-42-00 · CTIS ↗ · Hemic and Lymphatic Diseases Drug: Fitusiran	Phase 3	Ongoing	Belgium, Italy, Romania + 4 more
A multi-center, open-label, single-arm study to evaluate the efficacy and safety of oral rilzabrutinib in adults with immune thrombocytopenia (ITP) who failed first-line treatment 2025-522070-36-00 · CTIS ↗ · Immune System Diseases Drug: Rilzabrutinib	Phase 3	Ongoing	France, Spain, Italy + 6 more
An open-label, Phase 1/2, multicenter study of belumosudil in children aged 1 to <18 years requiring systemic treatment for active moderate-to-severe chronic graft versus host disease (cGVHD). 2024-511508-18-00 · CTIS ↗ · Immune System Diseases Drug: Belumosudil	Phase 1	Ongoing	France, Italy, Belgium + 3 more
A randomized, double-blind, placebo-controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of mucus plugging and other lung imaging parameters in patients with chronic obstructive pulmonary disease (AEOLUS) 2025-521268-37-00 · CTIS ↗ · Respiratory Tract Diseases Drug: Dupilumab	Phase 4	Ongoing	Netherlands, Hungary, France + 7 more

Drugs in Sanofi trials

76 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 36 more in the trial list above.

Conditions in Sanofi trials

82 conditions

Healthy Volunteers8 Asthma6 Dermatitis Atopic6 Crohn's Disease5 Chronic Obstructive Pulmonary Disease4Chronic Rhinosinusitis With Nasal Polyps4Type 1 Diabetes4 Multiple Sclerosis4 Colitis Ulcerative4Plasma Cell Myeloma3Ulcerative Colitis3Polyneuropathy, Inflammatory Demyelinating, Chronic3Type 1 Diabetes Mellitus3Pneumococcal Immunization3Plasma Cell Myeloma Refractory3Chronic Graft Versus Host Disease2Sickle Cell Disease2Glycogen Storage Disease Type II2Fabry Disease2 Hidradenitis Suppurativa2Prurigo Nodularis2Hemophilia A2Hemophilia2Meningococcal Infection2

By trial register

Register	Trials	Recruiting
Clinical trials in USA	107	51
Clinical trials in China	56	24
Clinical trials in UK	54	22
Clinical trials in India	14	1
Clinical trials in Ireland	4	1
EU register (CTIS)	15	—

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Healthy Volunteers

Sponsor	Trials
Vigonvita Life Sciences	6
Bristol-Myers Squibb	5
Hunan Kelun Pharmaceutical	4
Shanghai Minwei Biotechnology	3
Alnylam Pharmaceuticals	2
Karuna Therapeutics, Inc., a Bristol Myers Squibb company	2
Sanofi Pasteur, a Sanofi Company	2
American Laboratory Products Company	2
Xidian University	2
Technical University of Munich	1

Sponsors with the most current trials registered for this condition.

Questions about Sanofi trials

How many clinical trials does Sanofi sponsor?

Sanofi is the lead sponsor of 118 current trials on ClinicalTrials.gov in our USA, China, UK, India and Ireland registers, and 15 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Sanofi trials recruiting?

Yes. 59 of its 118 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Sanofi testing?

Its current trials name 76 drugs and biologicals as interventions. The most frequent are Dupilumab (12), Frexalimab (9), Rilzabrutinib (7), Amlitelimab (6) and Belumosudil (6). The number in brackets is how many of its trials name each drug.

Does Sanofi have clinical trials in Ireland?

Yes. 4 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Sanofi clinical trials